AMP01
Pre-clinical- Indications
- Cancer
Company intelligence / Profile preview
Therapeutic Window
Boston, Massachusetts, United Stateswindowtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Window Therapeutics leverages its proprietary BAM/BAC platform to develop cancer therapeutics that selectively target diseased tissue while minimizing toxicity to healthy cells. The company’s approach aims to expand the therapeutic window of various drug classes, but no clinical results have been published yet.
- Therapeutic areas
- OtherOncologyHematology
- Modalities
- Small moleculesBiologic-drug conjugatesImmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Therapeutic Window.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therapeutic Window.